{"id":2159,"date":"2021-10-10T14:04:07","date_gmt":"2021-10-10T06:04:07","guid":{"rendered":"http:\/\/oncolab.cn\/index.php\/2021\/10\/10\/%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac2%e7%ab%a0%ef%bc%9a%e4%ba%ba%e7%b1%bb%e8%82%bf%e7%98%a4%e5%be%ae%e7%8e%af%e5%a2%83%ef%bc%88%e4%b8%8b%ef%bc%89\/"},"modified":"2022-05-01T17:08:51","modified_gmt":"2022-05-01T09:08:51","slug":"%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac2%e7%ab%a0%ef%bc%9a%e4%ba%ba%e7%b1%bb%e8%82%bf%e7%98%a4%e5%be%ae%e7%8e%af%e5%a2%83%ef%bc%88%e4%b8%8b%ef%bc%89","status":"publish","type":"post","link":"http:\/\/oncolab.cn\/index.php\/2021\/10\/10\/%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac2%e7%ab%a0%ef%bc%9a%e4%ba%ba%e7%b1%bb%e8%82%bf%e7%98%a4%e5%be%ae%e7%8e%af%e5%a2%83%ef%bc%88%e4%b8%8b%ef%bc%89\/","title":{"rendered":"\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c2\u7ae0\uff1a\u4eba\u7c7b\u80bf\u7624\u5fae\u73af\u5883\uff08\u4e0b\uff09"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n

\u5728\u4e0a\u671f\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c2\u7ae0\uff1a\u4eba\u7c7b\u80bf\u7624\u5fae\u73af\u5883\uff08\u4e0a\uff09<\/a>\u4e2d\u5df2\u7ecf\u5bf9\u80bf\u7624\u514d\u75ab\u5b66\u53ca\u764c\u75c7\u7684\u53d1\u5c55\u8fdb\u884c\u4e86\u7b80\u8981\u4ecb\u7ecd\uff0c\u5e76\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u7684\u5404\u79cd\u6210\u5206\u5982\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de\u3001NK\u7ec6\u80de\u3001\u6811\u7a81\u72b6\u7ec6\u80de\u3001\u4e09\u7ea7\u6dcb\u5df4\u7ed3\u6784\u3001T\u7ec6\u80de\u3001B\u7ec6\u80de\u7b49\u8fdb\u884c\u4e86\u63cf\u8ff0\uff0c\u90a3\u4e48\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u7684\u8fd9\u4e9b\u6210\u5206\u5bf9\u60a3\u8005\u7684\u4e34\u5e8a\u9884\u540e\u8fd8\u6709\u4e00\u4e9b\u7597\u6cd5\u7684\u6548\u679c\u6709\u7740\u4ec0\u4e48\u6837\u7684\u610f\u4e49\u5462\uff0c\u8fd9\u5c06\u662f\u672c\u671f\u7684\u91cd\u70b9\u5185\u5bb9\u3002<\/p>\n

\u63d2\u64ad\u4e00\u6761\u5e7f\u544a\uff0c\u672c\u5b9e\u9a8c\u5ba4\u6709\u57fa\u7840\u533b\u5b66(\u514d\u75ab\u5b66)\u7814\u7a76\u751f\u62db\u751f\u540d\u989d\u5c11\u91cf(\u53ef\u63a5\u53d7\u63a8\u514d)\uff0c\u4e3b\u8981\u7814\u7a76\u65b9\u5411\u4e3a\u501f\u52a9\u5355\u7ec6\u80de\u5206\u6790\u6280\u672f\u63a2\u7d22\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u5bfc\u81f4\u514d\u75ab\u9003\u9038\u7684\u56e0\u7d20\u4ee5\u53ca\u901a\u8fc7\u5b9e\u9a8c\u9a8c\u8bc1\uff0c\u6709\u5174\u8da3\u7684\u53ef\u4ee5OncoLab\u5fae\u4fe1\u516c\u4f17\u53f7\u540e\u53f0\u53d1\u6d88\u606f\u8054\u7cfb\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

2.4 \u80bf\u7624\u5fae\u73af\u5883(TME)\u5f71\u54cd\u60a3\u8005\u7684\u4e34\u5e8a\u9884\u540e<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u514d\u75ab\u6d78\u6da6\u7684\u91cf\u5316\u53ca\u5176\u4e0e\u9884\u540e\u7684\u5173\u7cfb\u5df2\u7ecf\u670920\u591a\u5e74\u7684\u7814\u7a76\u5386\u53f2\u3002\u5728\u89c2\u5bdf\u5230\u5375\u5de2\u764c\u4e2dT\u7ec6\u80de\u5bc6\u5ea6\u8f83\u9ad8\u4e0e\u8f83\u957f\u7684\u751f\u5b58\u671f\u76f8\u5173\u540e\uff0cGalon\u3001Pag\u00e8s\u548cFridman\u9996\u6b21\u5728\u5927\u80a0\u764c(CRC)\u60a3\u8005\u7684\u5927\u961f\u5217\u7814\u7a76\u4e2d\u8bc1\u660e\u4e86\u8bb0\u5fc6T\u7ec6\u80de\u5bc6\u5ea6\u4e0e\u65e9\u671f\u8f6c\u79fb\u548c\u60a3\u8005\u751f\u5b58\u4e4b\u95f4\u7684\u5173\u7cfb\uff0c\u5728\u8fd9\u4e00\u9886\u57df\u53d6\u5f97\u4e86\u91cd\u5927\u7a81\u7834\u3002\u4ece\u90a3\u65f6\u8d77\uff0c\u514d\u75ab\u7ec4\u5316 (IHC)\u3001\u9ad8\u901a\u91cf\u81ea\u52a8\u5b9a\u91cf\u6210\u50cf\u6280\u672f\u7684\u53d1\u5c55\uff0c\u4f7f\u5f97\u5bf9TME \u514d\u75ab\u7ec6\u80de\u7ec4\u6210\u7684\u7814\u7a76\u5927\u5927\u589e\u591a\u3002\u968f\u7740\u9006\u8f6cT\u7ec6\u80de\u8870\u7aed\u7684\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u7597\u6cd5(CBT)\u7684\u51fa\u73b0\uff0c\u5168\u7403\u8bb8\u591a\u56e2\u961f\u5f00\u59cb\u7814\u7a76TME\u4e2d\u7684T\u7ec6\u80de\u4e30\u5ea6\u53ca\u5176\u4e0eCBT\u7684\u7ed3\u679c\u548c\/\u6216\u53cd\u5e94\u4e4b\u95f4\u7684\u8054\u7cfb\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

2.4.1 T\u7ec6\u80de<\/strong><\/p>\n<\/section>\n

\n
\n
\n

2.4.1.1 CD8+<\/sup> T\u7ec6\u80de<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

TME\u5185\u7684T\u7ec6\u80de\u4e30\u5ea6\u5df2\u7ecf\u5728\u5927\u591a\u6570\u80bf\u7624\u7c7b\u578b\u4e2d\u88ab\u5e7f\u6cdb\u7814\u7a76\u30022012\u5e74\uff0c\u672c\u4e66\u7f16\u8005\u53d1\u8868\u4e86\u4e00\u7bc7\u5173\u4e8e\u514d\u75ab\u7ec6\u80de\u7fa4\u80bf\u7624\u6d78\u6da6\u548c\u9884\u540e\u7684\u7efc\u8ff0\u3002\u6211\u4eec\u62a5\u9053\u4e86CD3+<\/sup> T\u7ec6\u80de\uff0cCD8+<\/sup>\u7ec6\u80de\u6bd2\u6027T\u7ec6\u80de\u548cCD45RO+<\/sup>\u8bb0\u5fc6T\u7ec6\u80de\u7684\u9ad8\u5bc6\u5ea6\u4e0e\u5927\u591a\u6570\u80bf\u7624(\u5305\u62ec\u9ed1\u8272\u7d20\u7624\u3001\u5934\u9888\u90e8\u3001\u4e73\u817a\u3001\u8180\u80f1\u3001\u5c3f\u8def\u4e0a\u76ae\u3001\u5375\u5de2\u3001\u7ed3\u76f4\u80a0\u764c\u548c\u80ba\u764c\uff09\u66f4\u957f\u7684\u65e0\u75c5\u751f\u5b58\u671f<\/span>(DFS)\u548c\/\u6216\u603b\u751f\u5b58\u671f(OS)\u76f8\u5173\uff0c\u800c\u80be\u900f\u660e\u7ec6\u80de\u764c(ccRCC)\u662f\u5c11\u89c1\u7684\u4f8b\u5916\u4e4b\u4e00\u3002\u6211\u4eec\u53bb\u5e74\u66f4\u65b0\u4e86\u8fd9\u4e9b\u6570\u636e\u5e76\u53d1\u73b0\u4e86\u7c7b\u4f3c\u7684\u7ed3\u679c\u3002\u6b64\u5916\uff0c\u6211\u4eec\u62a5\u9053\u4e86\u65b0\u7684\u80bf\u7624\u7c7b\u578b\uff0c\u5982\u80c3\u80a0\u9053\u95f4\u8d28\u7624\u3001\u7532\u72b6\u817a\u764c\u6216\u53e3\u54bd\u764c\uff0c\u5176\u4e2d\uff0cCD8+ <\/sup>\u7ec6\u80de\u6d78\u6da6\u4e0e\u826f\u597d\u9884\u540e\u76f8\u5173\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6211\u4eec\u8bc1\u5b9e\u4e86ccRCC\u4e2d CD8+ <\/sup>T \u7ec6\u80de\u7684\u4e0d\u826f\u9884\u540e\u76f8\u5173\u6027\uff0c\u65e0\u8bba\u662f\u5728\u80be\u539f\u53d1\u6027\u80bf\u7624\u8fd8\u662f\u5728ccRCC\u80ba\u8f6c\u79fb\u4e2d\u90fd\u662f\u5982\u6b64\u3002\u9664\u4e86ccRCC\uff0c\u5728\u80ba\u817a\u764c\u548cHCC\u7684\u7814\u7a76\u4e2d\u4e5f\u62a5\u9053\u4e86\u4e0eCD8+ <\/sup>T\u7ec6\u80de\u6d78\u6da6\u589e\u52a0\u76f8\u5173\u7684\u4e0d\u826f\u9884\u540e\uff0c\u8fd9\u4e0e\u5176\u4ed6\u5df2\u53d1\u8868\u7684\u7814\u7a76\u76f8\u77db\u76fe\u3002\u540c\u6837\u5728\u524d\u5217\u817a\u764c\u4e2d\uff0cCD8+ T\u7ec6\u80de\u5bc6\u5ea6\u4e0e\u9884\u540e\u4e0d\u826f\u76f8\u5173\uff0c\u4e0e\u6211\u4eec\u81ea\u5df1\u7684\u6570\u636e\u4e00\u81f4\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

CRC\u7684\u201c\u7ecf\u5178\u201d\u6848\u4f8b<\/strong><\/p>\n

\u7ed3\u76f4\u80a0\u764c\u662f\u80bf\u7624\u4e2d\u9ad8CD8+ <\/sup>T\u7ec6\u80de\u5bc6\u5ea6\u4e0e\u826f\u597d\u7684\u9884\u540e\u76f8\u5173\u7684\u7c7b\u578b\u3002\u4e8b\u5b9e\u4e0a\uff0cCD8+ <\/sup>T\u7ec6\u80de\u7684\u9ad8\u6d78\u6da6\uff0c\u5c24\u5176\u662f\u6548\u5e94\u8bb0\u5fc6\u4e9a\u578b (TEM)\uff0c\u4e0e\u4f4e\u8f6c\u79fb\u6269\u6563\u548cPFS \u3001 OS\u7684\u5ef6\u957f\u6709\u5173\uff0c\u8868\u660eT\u7ec6\u80de\u53ef\u4ee5\u63a7\u5236\u539f\u53d1\u6027\u80bf\u7624\u7684\u5c40\u90e8\u4fb5\u88ad\u5e76\u63d0\u4f9b\u957f\u671f\u7684\u5168\u8eab\u4fdd\u62a4\u4ee5\u9632\u6b62\u8f6c\u79fb\u3002<\/p>\n

\u6b64\u5916\uff0cIHC\u7814\u7a76\u8868\u660eT\u7ec6\u80de\u5728\u80bf\u7624\u4e2d\u5fc3\u548c\u6d78\u6da6\u8fb9\u7f18\u7684\u533a\u57df\u5316\u662f\u91cd\u8981\u7684\u3002Jerome Galon\u7684\u56e2\u961f\u5f00\u53d1\u7684\u514d\u75ab\u8bc4\u5206 (IS) \u65b9\u6cd5\u5728\u5168\u7403\u7ea64000\u540dCRC\u60a3\u8005\u4e2d\u6d4b\u91cf\u4e86\u4e2d\u5fc3\u4ee5\u53ca\u80bf\u7624\u7684\u4fb5\u88ad\u6027\u8fb9\u7f18\u7684CD3+ <\/sup>\u548c CD8+ <\/sup>T \u7ec6\u80de\u7684\u5bc6\u5ea6\u3002\u7ed3\u679c\u663e\u793a\u5373\u4f7f\u5728\u4e00\u4e9b\u9ad8T\u7ec6\u80de\u5bc6\u5ea6\u7684\u8f83\u5c0f\u80bf\u7624\u548cMSI-\u9633\u6027\u80bf\u7624\u4e2d\uff0cIS\u4e5f\u662f\u72ec\u7acb\u4e8eTNM\u5206\u671f\u548cMSI\u72b6\u6001\u7684\u9884\u540e\u56e0\u7d20\u3002\u6b64\u5916\uff0cIS\u5bf9\u65e9\u671f\u7ed3\u76f4\u80a0\u764c\u60a3\u8005\u7684\u9884\u540e\u9884\u6d4b\u66f4\u4e3a\u51c6\u786e\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

ccRCC\u7684\u201c\u7279\u6b8a\u201d\u6848\u4f8b<\/strong><\/p>\n

\u6211\u4eec\u6700\u8fd1\u62a5\u9053\u4e86ccRCC\u4e2dCD8+ <\/sup>T \u7ec6\u80de\u6d78\u6da6\u4e0e\u9884\u540e\u4e4b\u95f4\u5b58\u5728\u660e\u663e\u7684\u8d1f\u76f8\u5173\u3002\u5728\u4e00\u7ec4135\u4f8b\u539f\u53d1\u6027RCC\u80bf\u7624\u60a3\u8005\u4e2d\uff0c\u6839\u636e IHC\u8bc4\u4f30\uff0c\u6211\u4eec\u53d1\u73b0\u9ad8CD8+<\/sup>\u7ec6\u80de\u5bc6\u5ea6\u4e0eDFS<\/span>\u548cOS\u76f8\u5173\u3002\u8fd9\u4e9b\u7ed3\u679c\u5728 51 \u540d\uff08\u5207\u9664\u7684\uff09ccRCC \u80ba\u8f6c\u79fb\u60a3\u8005\u7684\u72ec\u7acb\u961f\u5217\u4e2d\u5f97\u5230\u4e86\u9a8c\u8bc1\u3002\u9ad8\u5bc6\u5ea6CD8+ <\/sup>T\u7ec6\u80de\u51fa\u73b0\u8fd9\u79cd\u4e0d\u826f\u9884\u540e\u7684\u6f5c\u5728\u673a\u5236\u5c1a\u4e0d\u5b8c\u5168\u6e05\u695a\uff0c\u4e0d\u8fc7<\/span>\u6211\u4eec\u53d1\u73b0\u5927\u591a\u6570\u7624\u5185T\u7ec6\u80de\u8868\u578b\u4e3a\u8870\u7aed\u8868\u578b\uff0c\u8fd9\u53cd\u6620\u4e86\u53ef\u80fd\u7531\u4e8e\u5b58\u5728\u8868\u578b\u4e0d\u6210\u719f\u7684\u529f\u80fd\u5931\u8c03\u6027\u6811\u7a81\u72b6\u7ec6\u80de\u4ece\u800c\u5bfc\u81f4\u6297\u539f\u9012\u5448\u53d7\u635f\uff08Fig 2.2Ad<\/span>\uff09\u3002\u8fd9\u4e9b\u529f\u80fd\u5931\u8c03\u6027\u6811\u7a81\u72b6\u7ec6\u80de\u8868\u8fbe\u6210\u719f DC \u7684 DC-Lamp \u6807\u5fd7\u7269\uff0c\u4f46\u7f3a\u4e4f\u6210\u719fDC\u8868\u8fbe\u7684\u9ad8\u6c34\u5e73MHC II\u7c7b\u5206\u5b50\u548c CD83\uff0c\u5b83\u4eec\u53ef\u80fd\u4e0eT\u7ec6\u80de\u6297\u80bf\u7624\u53cd\u5e94\u53d7\u635f\u6709\u5173\u3002\u540c\u6837\u5730\uff0c\u4e09\u7ea7\u6dcb\u5df4\u7ed3\u6784\uff08TLS\uff09\u5185DC\u5bc6\u5ea6\u8f83\u9ad8\u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u5bc6\u5ea6\u7684 CD8+ <\/sup>T\u4e0e\u826f\u597d\u7684\u9884\u540e\u76f8\u5173\u3002\u56e0\u6b64\uff0c\u6839\u636e\u6211\u4eec\u4e4b\u524d\u5728\u80ba\u764c\u4e2d\u7684\u89c2\u5bdf\uff0cTLS\u4e2d\u6210\u719fDC\u7684\u6297\u539f\u5448\u9012\u4f3c\u4e4e\u662f\u9a71\u52a8 ccRCC\u6297\u80bf\u7624\u53cd\u5e94\u7684\u5173\u952e\u3002\u6b64\u5916\uff0c\u6211\u4eec\u901a\u8fc7\u514d\u75ab\u8367\u5149 (IF) \u663e\u793aCD8+ <\/sup>T\u7ec6\u80de\u8868\u8fbe\u514d\u75ab\u8c03\u8282\u53d7\u4f53\uff0c\u5982PD-1 \u548c\/\u6216 LAG-3\uff0c\u8868\u660e\u8fd9\u662f\u9ad8\u5ea6\u8870\u7aed\u7684\u8868\u578b\uff0c\u5e76\u4e14\u4e24\u8005\u90fd\u4e0e\u4e0d\u826f\u9884\u540e\u76f8\u5173\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

2.4.1.2 CD4+ <\/sup>T ,TH2\u548cTH17<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4e0eCD8+<\/sup>T \u7ec6\u80de\u6d78\u6da6\u4e00\u6837\uff0cTh1 \u578b\u7684CD4+<\/sup>T\u7ec6\u80de\u6d78\u6da6\u589e\u52a0\u4e0e\u51e0\u4e4e\u6240\u6709\u7814\u7a76\u7684\u80bf\u7624\u7c7b\u578b\uff08\u5305\u62ec\u4e73\u817a\u764c\u6216 CRC\uff09\u7684\u826f\u597d\u9884\u540e\u76f8\u5173\u3002\u5176\u4ed6 T \u7ec6\u80de\u4e9a\u7fa4\uff08Th2\u3001Th17\uff09\u7684\u9884\u540e\u4ef7\u503c\u7814\u7a76\u8f83\u5c11\uff0c\u9996\u5148\u662f\u56e0\u4e3a\u5728\u5927\u591a\u6570\u80bf\u7624\u4e2d\u51fa\u73b0\u9891\u7387\u8f83\u4f4e\uff0c\u5176\u6b21\u662f\u4e13\u95e8\u8bc6\u522b\u8fd9\u4e9b\u4e9a\u7fa4\u5b58\u5728\u6280\u672f\u96be\u5ea6\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

2.4.1.3 \u8c03\u8282\u6027T\u7ec6\u80de\uff08Tregs\uff09<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Tregs \u7684\u4f8b\u5b50\u5f88\u6709\u8bf4\u670d\u529b\u3002\u9ad8Treg\u5bc6\u5ea6\u9996\u5148\u88ab\u8bc1\u5b9e\u4e0e\u5375\u5de2\u764c\u7684\u4e0d\u826f\u9884\u540e\u76f8\u5173\uff0c\u968f\u540e\u5728\u591a\u79cd\u80bf\u7624\u4e2d\u5f97\u5230\u8bc1\u5b9e\uff0c\u5982\u4e73\u817a\u764c\u3001\u80ba\u764c\u3001\u9ed1\u8272\u7d20\u7624\u6216\u7ed3\u76f4\u80a0\u764c\u3002\u7136\u800c\uff0c\u5176\u4ed6\u7814\u7a76\u62a5\u544a\u79f0\u5728\u7ed3\u76f4\u80a0\u764c\u3001\u8180\u80f1\u764c\u3001\u5934\u9888\u764c\u6216\u5375\u5de2\u764c\u4e2d\uff0c\u9ad8\u5bc6\u5ea6Treg\u4e0e\u8f83\u957f\u7684OS\u76f8\u5173\u3002\u4ea7\u751f\u8fd9\u4e9b\u76f8\u53cd\u7ed3\u679c\u7684\u539f\u56e0\u4e4b\u4e00\u662f\u5f88\u96be\u786e\u5b9aTreg\u4e9a\u7fa4\u3002Treg \u662f\u4e00\u4e2a\u5f02\u8d28\u6027\u8f83\u9ad8\u7684\u7fa4\u4f53\uff0c\u7406\u60f3\u60c5\u51b5\u4e0b\u5e94\u8be5\u901a\u8fc7\u591a\u79cd\u6807\u5fd7\u7269\uff08CD4+<\/sup>\u3001CD25+<\/sup>\u3001Foxp3+<\/sup>\u3001T \u7ec6\u80de\uff09\u6765\u8054\u5408\u8bc6\u522b\u3002\u591a\u8272\u8367\u5149\u6210\u50cf\u6280\u672f\u7684\u53d1\u5c55\u4f7f\u5f97\u53ef\u68c0\u6d4b\u5230\u7684\u7ec6\u80de\u8868\u9762\u6807\u8bb0\u7269\u6570\u91cf\u663e\u8457\u589e\u52a0\u3002\u9664\u4e86\u6280\u672f\u6311\u6218\uff0c\u8fd9\u4e9b\u7ed3\u679c\u663e\u793a\u514d\u75ab\u7ec6\u80de\u7fa4\u5bf9\u9884\u540e\u7684\u5f71\u54cd\u53d6\u51b3\u4e8e\u80bf\u7624\u7c7b\u578b\u548cTME\u72b6\u6001\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
<\/section>\n<\/section>\n
\n

2.4.2 B\u7ec6\u80de<\/strong><\/p>\n<\/section>\n

\n
\n
\n

B\u7ec6\u80de\u5728\u6297\u80bf\u7624\u514d\u75ab\u4e2d\u7684\u79ef\u6781\u6216\u6d88\u6781\u4f5c\u7528\u5df2\u7ecf\u8ba8\u8bba\u4e86\u5f88\u591a\u5e74\uff0c\u4e3b\u8981\u4ee5\u5c0f\u9f20\u7814\u7a76\u4e3a\u57fa\u7840\u3002\u4e0e T \u7ec6\u80de\u76f8\u6bd4\uff0c\u5f88\u5c11\u6709\u4e34\u5e8a\u7814\u7a76\u62a5\u9053\u80bf\u7624\u5185 B \u7ec6\u80de\u7684\u9884\u540e\u4f5c\u7528\u3002\u5927\u591a\u6570\u4e34\u5e8a\u7814\u7a76\u8868\u660e\uff0cTME\u5185\u9ad8\u5bc6\u5ea6\u7684 B \u7ec6\u80de\u4e0e\u66f4\u597d\u7684\u9884\u540e\u76f8\u5173\uff0c\u5305\u62ec\u4e73\u817a\u764c\u3001NSCLC\u3001\u5934\u9888\u764c\u3001\u5375\u5de2\u764c\u3001\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u3001\u80c6\u9053\u764c\u548c\u539f\u53d1\u6027\u76ae\u80a4\u9ed1\u8272\u7d20\u7624\u3002\u51e0\u79cd\u975e\u6392\u4ed6\u6027\u673a\u5236\u53ef\u4ee5\u89e3\u91ca B \u7ec6\u80de\u5728\u6297\u80bf\u7624\u514d\u75ab\u53cd\u5e94\u4e2d\u7684\u79ef\u6781\u4f5c\u7528\uff0c\u6709\u4e9b\u662f\u6297\u4f53\u4f9d\u8d56\u6027\u7684\uff0c\u56e0\u4e3a\u5b83\u4eec\u80fd\u591f\u89e6\u53d1\u8865\u4f53\u548c\u6297\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u6bd2\u6027\u4f5c\u7528\uff08CDC \u548c ADCC\uff09\uff0c\u6216\u8005\u5f62\u6210\u514d\u75ab\u590d\u5408\u7269\u6fc0\u6d3b\u6297\u539f\u63d0\u5448\u7ec6\u80de\uff0c\u8fdb\u800c\u6fc0\u6d3bCD4\u548cCD8+ <\/sup>T \u7ec6\u80de\u53cd\u5e94\u3002\u4e8b\u5b9e\u4e0a\uff0c\u5df2\u6709\u7814\u7a76\u8868\u660eB\u7ec6\u80de\u5728CD4+ <\/sup>T \u7ec6\u80de\u7684\u521d\u59cb\u542f\u52a8\u548c\u6269\u589e\u8fc7\u7a0b\u4e2d\u53d1\u6325\u91cd\u8981\u4f5c\u7528\uff0c\u8fd8\u6709\u62a5\u9053\u663e\u793a\u5b83\u80fd\u591f\u5c06\u6297\u539f\u4ea4\u53c9\u5448\u9012\u7ed9CD8+ <\/sup>T \u7ec6\u80de\uff0c\u5e76\u4e14\u53ef\u4ee5\u4fc3\u8fdb\u7ec6\u80de\u6bd2\u6027 T \u6dcb\u5df4\u7ec6\u80de\u7684\u5b58\u6d3b\u548c\u589e\u6b96\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u76f8\u53cd\uff0c\u5f88\u5c11\u6709\u4e34\u5e8a\u7814\u7a76\u62a5\u544aB\u7ec6\u80de\u5728TME\u4e2d\u7684\u4fc3\u80bf\u7624\u4f5c\u7528\u3002\u5b83\u53ef\u80fd\u901a\u8fc7\u7ef4\u6301\u6162\u6027\u708e\u75c7\u3001\u4fc3\u8fdb\u65b0\u8840\u7ba1\u751f\u6210\u548c\/\u6216\u76f4\u63a5\u6291\u5236\u7ec6\u80de\u6bd2\u6027T\u7ec6\u80de\u53cd\u5e94\u6765\u53d1\u6325\u4fc3\u80bf\u7624\u4f5c\u7528\u3002\u6b64\u5916\uff0c\u5df2\u7ecf\u53d1\u73b0\u4e86\u4e00\u79cd\u79f0\u4e3a\u201cBregs\u201d\u7684\u514d\u75ab\u8c03\u8282B\u7ec6\u80de\u4e9a\u7fa4\uff0c\u8be5\u4e9a\u7fa4\u5df2\u88ab\u8bc1\u660e\u6709\u5229\u4e8eTregs\u7684\u5206\u5316\u548c\u62db\u52df\uff0c\u4ece\u800c\u653e\u5927\u514d\u75ab\u6291\u5236\u73af\u5883\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u9664\u4e86 B \u7ec6\u80de\u7684\u5bc6\u5ea6\u4e4b\u5916\uff0c\u8d8a\u6765\u8d8a\u591a\u7684\u7814\u7a76\u62a5\u544a\u79f0\uff0c\u8fd9\u4e9b\u7ec6\u80de\u7684\u7a7a\u95f4\u5b9a\u4f4d\u5bf9\u60a3\u8005\u7684\u9884\u540e\u6709\u5f71\u54cd\u3002\u7279\u522b\u662f TLS \u7279\u6709\u7684\u6ee4\u6ce1\u578bB\u7ec6\u80de\u5bc6\u5ea6<\/span>\u4e0e\u9884\u540e\u5448\u6b63\u76f8\u5173\u3002M.C.Dieu-Nojean\u548ccol\u7684\u7814\u7a76\u8868\u660e TLS \u5185 B \u7ec6\u80de\u5bc6\u5ea6\u7684\u589e\u52a0\u4e0e\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09 \u60a3\u8005\u7684\u751f\u5b58\u671f\u5ef6\u957f\u6709\u5173\uff0c\u5728CRC\u548c\u53e3\u8154\u9cde\u764c\u4e2d\u4e5f\u6709\u7c7b\u4f3c\u7684\u62a5\u9053\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

2.4.3 \u5de8\u566c\u7ec6\u80de<\/strong><\/p>\n<\/section>\n

\n
\n
\n

\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de (TAM) \u662f TME \u7684\u4e3b\u8981\u7ec4\u6210\u90e8\u5206\uff0c\u5b58\u5728\u4e8e\u80bf\u7624\u6838\u5fc3\u548c\u6d78\u6da6\u8fb9\u7f18\u3002TAM \u7684\u9884\u540e\u4ef7\u503c\u4f3c\u4e4e\u53d6\u51b3\u4e8e\u80bf\u7624\u7c7b\u578b\u3002TAM \u5bc6\u5ea6\u7684\u589e\u52a0\u4e0e\u7ed3\u76f4\u80a0\u764c\u3001\u809d\u764c\u3001\u524d\u5217\u817a\u764c\u548c\u5bab\u9888\u764c\u7684\u826f\u597d\u9884\u540e\u76f8\u5173\u3002\u76f8\u53cd\uff0c\u5728\u5b50\u5bab\u5185\u819c\u3001\u80c3\u3001\u5c3f\u8def\u4e0a\u76ae\u3001\u809d\u764c\u3001\u9ed1\u8272\u7d20\u7624\u3001\u4e73\u817a\u3001\u5375\u5de2\u3001\u8180\u80f1\u3001\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u548c\u539f\u53d1\u6027CRC\u4e2d\uff0cTAM\u5bc6\u5ea6\u589e\u52a0\u4e0e\u9884\u540e\u4e0d\u826f\u6709\u5173\u3002\u8fd9\u4e9b\u5dee\u5f02\u53ef\u4ee5\u7528\u8fd9\u4e9b\u7ec6\u80de\u7684\u53ef\u5851\u6027\u6765\u89e3\u91ca\uff0c\u56e0\u4e3a\u6211\u4eec\u77e5\u9053TAM\u6709\u4e24\u4e2a\u4e9a\u578b\uff0c\u5b83\u4eec\u53ef\u4ee5\u4ece\u4fc3\u80bf\u7624\u529f\u80fd (M2) \u8f6c\u6362\u4e3a\u6297\u80bf\u7624\u529f\u80fd (M1)\uff0c\u53cd\u4e4b\u4ea6\u7136\u3002M2 TAMs \u7684\u751f\u5b58\u671f\u8f83\u77ed\uff0c\u800c M1 TAMs \u7684\u751f\u5b58\u671f\u8f83\u957f\u3002\u4e0d\u5e78\u7684\u662f\uff0c\u6ca1\u6709\u7279\u5b9a\u7684\u6216\u4e00\u81f4\u540c\u610f\u7684\u6807\u5fd7\u7269\u6765\u5b9a\u4e49 M1\/M2 TAMs\u3002\u5927\u591a\u6570\u7814\u7a76\u4f7f\u7528CD11c\u6216NOS2\u6807\u8bb0M1 TAMs\uff0c\u4f7f\u7528CD163\u3001CD204\u6216CD206\u6807\u8bb0M2 TAMs\uff0c\u4f46\u8fd9\u4e9b\u6807\u5fd7\u7269\u7684\u4f7f\u7528\u4ecd\u5b58\u5728\u4e89\u8bae\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u80bf\u7624\u5305\u542b\u53e6\u4e00\u79cd\u4e0d\u540c\u7684\u9aa8\u9ad3\u6765\u6e90\u7684\u7ec6\u80de\u4e9a\u7fa4\uff0c\u9aa8\u9ad3\u6765\u6e90\u6291\u5236\u6027\u7ec6\u80de(MDSC)\u3002\u8fd9\u79cd\u7ec6\u80de\u5177\u6709\u4e0d\u6210\u719f\u7684\u8868\u578b\u5e76\u5177\u6709\u8f83\u5f3a\u7684\u514d\u75ab\u6291\u5236\u6d3b\u6027\u3002\u5728\u4eba\u7c7bTME\u4e2d\u4ecd\u7136\u9700\u8981\u7279\u5b9a\u7684\u5f3a\u5927\u7684\u5de5\u5177\u6765\u8bc6\u522b\u5b83\u4eec\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

2.4.4 \u8bc4\u4f30\u80bf\u7624\u514d\u75ab\u7ec6\u80de\u6d78\u6da6\u7684\u65b0\u6280\u672f<\/strong><\/p>\n<\/section>\n

\n
\n
\n

\u5b9a\u91cf\u80bf\u7624\u6d78\u6da6\u514d\u75ab\u7ec6\u80de\u6700\u5e38\u7528\u7684\u65b9\u6cd5\u662f\u901a\u8fc7IHC\u6216IF\u68c0\u6d4b\u7279\u5f02\u6027\u6807\u5fd7\u86cb\u767d\u7684\u8868\u8fbe\u3002\u8fd9\u4e9b\u6280\u672f\u5728\u8fc7\u53bb\u5341\u5e74\u4e2d\u5f97\u5230\u4e86\u6539\u8fdb\uff0c\u5df2\u7ecf\u53ef\u4ee5\u68c0\u6d4b\u591a\u79cd\u86cb\u767d\u8d28\uff08\u591a\u91cd IHC \u6216 IF\uff09\u5e76\u81ea\u52a8\u91cf\u5316\u7ec6\u80de\u3002\u7136\u800c\uff0c\u5b83\u4eec\u4ecd\u7136\u6602\u8d35\u4e14\u96be\u4ee5\u5b9e\u73b0\u5b9e\u9a8c\u5ba4\u6807\u51c6\u5316\uff0c<\/span>\u5e76\u4e14\u53ef\u7528\u7684\u6297\u4f53\u53ef\u80fd\u7f3a\u4e4f\u51c6\u786e\u68c0\u6d4b\u67d0\u4e9b\u514d\u75ab\u7ec6\u80de\u7fa4\u7684\u654f\u611f\u6027\u6216\u7279\u5f02\u6027\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4eba\u4eec\u5df2\u7ecf\u52aa\u529b\u4f7f\u7528\u8f6c\u5f55\u7ec4\u6765\u8bc4\u4f30 TME \u7684\u7ec4\u6210\u3002\u7136\u800c\uff0c\u76f4\u5230\u6700\u8fd1\uff0c\u4fe1\u53f7\u7684\u53ef\u53d8\u6027\u9650\u5236\u4e86\u5b83\u7684\u9002\u7528\u6027\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

CIBERSORT\u6216MCP-counter\u7b49\u65b0\u65b9\u6cd5\u65e8\u5728\u63d0\u4f9b\u975e\u5e38\u7cbe\u786e\u7684\u975e\u5747\u8d28\u6837\u54c1\u4e2d\u7ec6\u80de\u542b\u91cf\u7684\u5b9a\u91cf\u4fe1\u606f\u3002\u4f7f\u7528 MCP-counter\uff0c\u6211\u4eec\u8bc4\u4f30\u4e8625\u79cd\u4e0d\u540c\u764c\u75c7\uff08n = 19,000\uff09\u7684\u8f6c\u5f55\u7ec4\u6570\u636e\u4e2d\u514d\u75ab\u7ec6\u80de\u3001\u6210\u7ea4\u7ef4\u7ec6\u80de\u548c\u5185\u76ae\u7ec6\u80de\u6d78\u6da6\u7684\u4e30\u5ea6\u3002\u7ed3\u679c\u663e\u793a\u4e86\u4e0d\u540c\u764c\u75c7\u4e2d\u80bf\u7624\u5fae\u73af\u5883\u7ec6\u80de\u7ec4\u6210\u7684\u76f8\u5bf9\u5f02\u8d28\u6027\uff0c\u5e76\u8bc1\u5b9e CD8+<\/sup>\u6216\u7ec6\u80de\u6bd2\u6027 T \u7ec6\u80de\u7684\u5bc6\u5ea6<\/span>\u4e0e\u5927\u591a\u6570\u764c\u75c7\u7c7b\u578b\u7684\u826f\u597d\u9884\u540e\u76f8\u5173\uff08Fig2.3<\/span>\uff09\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
<\/section>\n<\/section>\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

Fig 2.3<\/span> \u4eba\u7c7b\u5b9e\u4f53\u80bf\u7624\u4e2d\u6d78\u6da6\u6027\u514d\u75ab\u7ec6\u80de\u548c\u57fa\u8d28\u7ec6\u80de\u7684\u4e30\u5ea6\u53ca\u5176\u9884\u540e\u610f\u4e49\u7684\u8bc4\u4f30\u3002\u5de6:\u5728\u4e09\u4e2a\u8f6c\u5f55\u7ec4\u5e73\u53f0\u4e0a\uff0c\u6076\u6027\u7ec4\u7ec7(\u8d85\u8fc719,000\u4e2a\u80bf\u7624)\u7684MCP-counter\u8bc4\u4f30\u3002\u53f3:\u4e0e\u4eba\u5b9e\u4f53\u80bf\u7624MCP-counter\u8bc4\u5206\u76f8\u5173\u7684\u5355\u53d8\u91cf\u9884\u540e\u503c(\u603b\u751f\u5b58\u671f)\u3002\u7eff\u8272\u4ee3\u8868\u663e\u8457\u7684\u9884\u540e\u826f\u597d\u5f71\u54cd\uff0c\u7d2b\u8272\u4ee3\u8868\u663e\u8457\u7684\u9884\u540e\u4e0d\u826f\u5f71\u54cd\u3002\u7070\u8272\u8868\u793a\u6ca1\u6709\u663e\u7740\u7684\u9884\u540e\u5f71\u54cd\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

2.5 TME\u4f5c\u4e3a\u6cbb\u7597\u5e94\u7b54\u53cd\u5e94\u7684\u9884\u6d4b\u56e0\u5b50<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u9776\u5411\u80bf\u7624\u7ec6\u80de\u53ca\u5176\u5206\u5b50\u6539\u53d8\u51e0\u5341\u5e74\u540e\uff0c\u65b0\u7684\u80bf\u7624\u514d\u75ab\uff08IO\uff09\u836f\u7269\u5982 CBT \u63ed\u793a\u4e86 TME \u7684\u5173\u952e\u4f5c\u7528\u3002\u76ee\u524d\u6279\u51c6\u7684 CBT \u9776\u70b9\u662f CTLA-4 (ipilimumab) \u6216 PD-1 \/ PD-L1 (nivolumab, pembrolizumab, atezolizumab, avelumab\uff09\u3002\u8fd9\u4e9b mAb\u53ef \u963b\u65ad T \u7ec6\u80de\u4e0e APC \u6216\u80bf\u7624\u7ec6\u80de\u76f8\u4e92\u4f5c\u7528\u540e\u63a5\u6536\u5230\u7684\u8d1f\u4fe1\u53f7\uff0c\u4ece\u800c\u9006\u8f6c T \u7ec6\u80de\u7684\u8870\u7aed\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u7531\u4e8e\u8fd9\u4e9b\u8bd5\u5242\u7684\u4e3b\u8981\u76ee\u6807\u662f\u80bf\u7624\u6d78\u6da6\u6027T\u7ec6\u80de\uff0c\u56e0\u6b64\u9884\u6d4bCBT\u7597\u6548\u7684\u7814\u7a76\u4e00\u76f4\u96c6\u4e2d\u5728\u6cbb\u7597\u524d\u548c\/\u6216\u6cbb\u7597\u671f\u95f4\u7684T\u7ec6\u80de\u5bc6\u5ea6\u3001\u5b9a\u4f4d\u3001\u8868\u578b\u548c\u529f\u80fd\u7b49\u65b9\u9762\u7684\u7279\u5f81\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5176\u4ed6\u4f17\u6240\u5468\u77e5\u7684\u548c\u6709\u4e89\u8bae\u7684\u5019\u9009\u836f\u7269\u4ecd\u88ab\u4f5c\u4e3a\u201c\u7597\u6548\u7684\u751f\u7269\u6807\u5fd7\u7269\u201d\u8fdb\u884c\u7814\u7a76\uff0c\u5982\u514d\u75ab\u7403\u86cb\u767d\u8868\u8fbePD-L1\u6216\u65b0\u6297\u539f\/\u7a81\u53d8\u8d1f\u8377\uff0c\u4f46\u4e0d\u5728\u672c\u7ae0\u7684\u4ecb\u7ecd\u8303\u56f4\u5185\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

2.5.1 \u6765\u81ea\u68c0\u67e5\u70b9\u963b\u65ad\u6cbb\u7597\u60a3\u8005\u7684\u65b0\u6570\u636e<\/strong><\/p>\n<\/section>\n

\n
\n
\n

2.5.1.1 \u80bf\u7624\u6d78\u6da6\u6027\u6dcb\u5df4\u7ec6\u80de<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u968f\u7740\u63a5\u53d7\u6297 PD-1\/PD-L1 \u6cbb\u7597\u7684\u60a3\u8005\u6570\u91cf\u4e0d\u65ad\u589e\u52a0\uff0c\u6709\u5173\u8fd9\u4e9b\u7597\u6cd5\u5bf9 TME \u7684\u836f\u6548\u5b66\u5f71\u54cd\u7684\u8f6c\u5316\u6570\u636e\u6b63\u5728\u4e0d\u65ad\u51fa\u73b0\u3002Tumeh\u7b49\u4eba\u62a5\u9053\uff0c\u5728\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u4e2d\uff0cpembrolizumab(\u6297PD -1)\u5e94\u7b54\u60a3\u8005\u7684CD8 TILs(\u80bf\u7624\u6d78\u6da6\u6027CD8+<\/sup>T\u6dcb\u5df4\u7ec6\u80de)\u57fa\u7ebf\u5bc6\u5ea6\u6c34\u5e73\u66f4\u9ad8\u3002\u4e0e ipilimumab \u4e00\u6837\uff0c\u6cbb\u7597\u4e2d\u7684\u8fde\u7eed\u6d3b\u68c0\u663e\u793a\u5e94\u7b54\u7ec4\u4e2d CD8+<\/sup> TIL\u7684\u5bc6\u5ea6\u589e\u52a0\u3002\u5728\u53e6\u4e00\u9879\u63a2\u7d22\u6027\u7814\u7a76\u4e2d\uff0c53 \u540d\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u5728\u6cbb\u7597\u524d\u548c\u6cbb\u7597\u65f6\u8fdb\u884c\u4e86\u8fde\u7eed\u6d3b\u68c0\uff0c\u8fd9\u4e9b\u60a3\u8005\u9996\u5148\u63a5\u53d7ipilimumab(\u6297CTLA-4)\u6cbb\u7597\uff0c\u7136\u540e\u63a5\u53d7\u6297 PD-1\uff08pembrolizumab\uff09<\/span>\u6cbb\u7597\u3002TME \u7684 IHC \u5206\u6790\u663e\u793a\uff0c\u6cbb\u7597\u65e9\u671f CD8+ <\/sup>TIL \u5bc6\u5ea6\u7684\u589e\u52a0\u4e0e\u5bf9 ipilimumab \u7684\u53cd\u5e94\u6709\u5173\uff0c\u800c TIL\u57fa\u7ebf\u5bc6\u5ea6\u5219\u4e0e\u4e4b\u65e0\u5173\u3002\u572846\u4f8b ipilimumab \u6cbb\u7597\u8fdb\u5c55\u540e\u63a5\u53d7\u6297 PD-1 \u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0c\u6709\u5e94\u7b54\u8005\u4e0e\u65e0\u5e94\u7b54\u8005\u9884\u5904\u7406\u6837\u672c\u4e2dCD8+<\/sup>\u3001CD3+<\/sup>\u3001CD45RO+<\/sup> T\u7ec6\u80de\u5bc6\u5ea6\u5dee\u5f02\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u6b64\u5916\uff0c\u5728\u65e9\u671f\u6cbb\u7597\u80bf\u7624\u6837\u672c\u4e2d\u89c2\u5bdf\u5230 T \u7ec6\u80de\u4e9a\u7fa4\u6807\u5fd7\u7269CD8\u3001CD4 \u548c CD3\uff0c\u4ee5\u53ca\u514d\u75ab\u8c03\u8282\u5206\u5b50 PD-1 \u548c LAG3 \u8868\u8fbe\u5177\u6709\u975e\u5e38\u663e\u8457\u7684\u7edf\u8ba1\u5b66\u5dee\u5f02\u3002\u603b\u4e4b\uff0c\u8fd9\u4e9b\u7ed3\u679c\u8868\u660e\u4e86 CBT \u5bf9 T \u7ec6\u80de\u53cd\u5e94\u7684\u5f71\u54cd<\/span>\u3002\u6b64\u5916\uff0c\u4f5c\u8005\u62a5\u9053\u4e86\u5728\u6cbb\u7597\u65e9\u671f\u6d3b\u68c0\u6837\u672c\u4e2d\uff0c\u6709\u5e94\u7b54\u8005\u4e0e\u65e0\u5e94\u7b54\u8005\u76f8\u6bd4\uff0c\u80bf\u7624\u4e2d\u5fc3(TC)\u7684CD8+ <\/sup>TIL\u76f8\u5bf9\u4e8e\u4fb5\u88ad\u8fb9\u7f18\uff08invasive margin\uff0cIM)\u7684\u6bd4\u4f8b\u589e\u52a0\uff0c\u8868\u660e\u6cbb\u7597\u540e\u4eceIM\u5230TC\u7684TIL\u6d78\u6da6\u3002\u6700\u540e\uff0c\u901a\u8fc7\u57fa\u56e0\u8868\u8fbe\u5206\u6790\u8bc1\u5b9e\u4e86 IHC \u7684\u7ed3\u679c\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u53e6\u4e00\u7ec4\u7814\u7a76\u5bf9 40 \u540d\u63a5\u53d7\u6297 PD-1 \u6cbb\u7597\u7684\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u60a3\u8005\uff08\u53d1\u73b0\u961f\u5217\u548c\u9a8c\u8bc1\u5404 20 \u540d\u60a3\u8005\uff09\u7684 TIL\uff08\u6d41\u5f0f\u7ec6\u80de\u672f\uff09\u8fdb\u884c\u4e86\u8868\u578b\u5206\u6790\u3002\u5728\u591a\u53d8\u91cf\u5206\u6790\u4e2d\uff0cTIL \u7684 CTLA4 \u8868\u8fbe\u662f\u552f\u4e00\u4e0e\u4e34\u5e8a\u53cd\u5e94\u663e\u8457\u76f8\u5173\u7684\u53c2\u6570\u3002\u6709\u6548\u7387 (RR) \u548c PFS \u4e0e CTLA-4hiPD-1hi CD8+ <\/sup>TIL \u7684\u76f8\u5bf9\u4e30\u5ea6\u663e\u8457\u76f8\u5173\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u4e00\u9879\u9488\u5bf9\u63a5\u53d7 atezolizumab\uff08\u6297 PD-L1\uff09\u6cbb\u7597\u7684\u60a3\u8005\u7684\u591a\u961f\u5217 I \u671f\u7814\u7a76\u4e2d\uff0cIHC \u7ed3\u679c\u663e\u793a CD8 \u7684\u5bc6\u5ea6\u548c\u9ad8 Teff \u7279\u5f81\uff08\u53d7\u5e72\u6270\u7d20\u03b3\uff08IFNg\uff09\u8c03\u8282\u7684\u57fa\u56e0\uff0c\u5305\u62ec IFNg\u3001CD8A\u3001\u9897\u7c92\u9176 A\u3001\u9897\u7c92\u9176 B\u3001EOMES \u548c\u7a7f\u5b54\u7d20\uff09\u4e0e\u9ed1\u8272\u7d20\u7624\u7684\u53cd\u5e94\u76f8\u5173\uff0c\u4f46\u5728 RCC \u4e2d\u672a\u89c2\u5bdf\u5230\u4e0e\u597d\u7684\u4e34\u5e8a\u7597\u6548\u76f8\u5173\u3002\u7136\u800c\uff0c\u57fa\u56e0\u8868\u8fbe\u6240\u63ed\u793a\u7684\u8f83\u9ad8\u7684 Teff \u4e0e Treg \u6bd4\u7387\u4e0e RCC \u4e2d\u7684 atezolizumab \u53cd\u5e94\u76f8\u5173\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6700\u8fd1\u62a5\u9053\u4e86\u4e00\u9879\u8f6c\u5316\u7814\u7a76\uff0c\u8be5\u7814\u7a76\u65e8\u5728\u7814\u7a76\u5728mRCC\u4e2dVEGF\u963b\u65ad\u5242bevacizumab\u5982\u4f55\u589e\u5f3aatezolizumab PD-L1 \u68c0\u67e5\u70b9\u6291\u5236\u7597\u6cd5\u3002\u4f5c\u8005\u8868\u660e\uff0c\u5355\u72ec\u4f7f\u7528bevacizumab<\/span>\u503e\u5411\u4e8e\u589e\u52a0\u4e0e T-helper 1 (Th1) \u8d8b\u5316\u56e0\u5b50\u548c CD8 T \u6548\u5e94\u5b50\u76f8\u5173\u7684\u57fa\u56e0\u7279\u5f81\uff0c\u800c\u4e0e atezolizumab \u7684\u7ec4\u5408\u8fdb\u4e00\u6b65\u589e\u52a0\u4e86\u8fd9\u4e9b\u7279\u5f81\u7684\u8868\u8fbe\u3002IHC \u663e\u793a\u51fa\u7c7b\u4f3c\u7684\u7ed3\u679c\uff0cbevacizumab<\/span>\u6cbb\u7597\u540e CD8+ <\/sup>\u5bc6\u5ea6\u589e\u52a0\uff0c\u8fd9\u5728\u7ec4\u5408\u4e2d\u66f4\u4e3a\u660e\u663e\u3002\u6709\u8da3\u7684\u662f\uff0cCD8+ <\/sup>TIL \u5bc6\u5ea6\u7684\u589e\u52a0\u4f3c\u4e4e\u53cd\u6620\u4e86\u5411\u80bf\u7624\u8f6c\u79fb\u6982\u7387\u7684\u589e\u52a0\uff0c\u800c\u4e0d\u662f\u539f\u4f4d\u589e\u6b96\u6982\u7387\u7684\u589e\u52a0\uff08CD8+ <\/sup>TIL \u4e2d Ki67+\/Ki67- \u7684\u6bd4\u7387\u4e0d\u53d8\uff09\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

2.5.2 \u4ece\u5206\u5b50\u5230\u514d\u75ab\u7279\u5f81<\/strong><\/p>\n<\/section>\n

\n
\n
\n

\u514d\u75ab\u9003\u9038\u662f\u5bf9\u8bb8\u591a\u5168\u8eab\u7597\u6cd5\uff08\u5305\u62ec\u6297\u8840\u7ba1\u751f\u6210\u836f\u7269\u7b49\u9776\u5411\u7597\u6cd5\uff09\u4ea7\u751f\u8010\u836f\u6027\u7684\u91cd\u8981\u673a\u5236\u3002\u4e8b\u5b9e\u4e0a\uff0c\u514d\u75ab\u9003\u9038\u662f ccRCC \u4e2d VEGFR-TKI \u8010\u836f\u7684\u4e3b\u8981\u673a\u5236\u4e4b\u4e00 \u3002\u6700\u8fd1\u6709\u62a5\u9053\u79f0\uff0c\u4f7f\u7528\u8f6c\u5f55\u7ec4\u5b66\u5206\u6790\uff0csunitinib (VEGFR-TKI) \u6cbb\u7597\u7684\u8f6c\u79fb\u6027 ccRCC \u53ef\u5206\u4e3a\u56db\u4e2a\u4e0d\u540c\u7684\u5206\u5b50\u5206\u578b\uff08ccrcc1 \u81f3 4\uff09\u3002\u56db\u7ec4\u60a3\u8005\u9884\u540e\u660e\u663e\u4e0d\u540c\uff0cccrrcc1 \u548c ccrrcc 4 \u7684\u5b58\u6d3b\u7387\u6700\u4f4e\uff0c\u5bf9sunitinib\u7684\u53cd\u5e94\u6700\u5dee\u3002\u6709\u8da3\u7684\u662f\uff0c\u6211\u4eec\u53d1\u73b0\u514d\u75ab\u7ec6\u80de\u6d78\u6da6\u5728\u56db\u7ec4\u5206\u578b\u7684\u60a3\u8005\u4e2d\u6709\u660e\u663e\u5dee\u5f02\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4f8b\u5982\uff0cccrcc4 \u80bf\u7624\u7684 T \u7ec6\u80de\u6d78\u6da6\u7a0b\u5ea6\u6700\u9ad8\uff0c\u514d\u75ab\u6291\u5236\u6807\u5fd7\u7269\u5982 PD-L1\u3001PD-1\u3001LAG-3\u3001TIM-3 \u7684\u8868\u8fbe\u6700\u9ad8\uff0c\u8868\u660e\u8fd9\u4e9b\u80bf\u7624\u4e2d\u7684 T \u7ec6\u80de\u5df2\u8017\u7aed\u3002\u76f8\u53cd\uff0c\u540c\u6837\u4e0e\u4e0d\u826f\u9884\u540e\u76f8\u5173\u7684 ccrcc1 \u80bf\u7624\u5177\u6709\u6700\u5dee\u7684 T \u7ec6\u80de\u6d78\u6da6\u548c\u4f4e\u8868\u8fbe\u7684 T \u7ec6\u80de\u53d7\u4f53\u6807\u5fd7\u7269\u3002\u7531\u4e8e CD8+ <\/sup>\u6d78\u6da6\u80bf\u7624\u7684\u5bc6\u5ea6\u4e0e CBT \u7597\u6548\u76f8\u5173\uff0c\u6211\u4eec\u63d0\u51fa\u4e86 ccrcc4 \u53ef\u4ee5\u5bf9 PD-1\/PD-L1 \u963b\u65ad\u4ea7\u751f\u53cd\u5e94\u7684\u5047\u8bbe\u3002\u76f8\u6bd4\u4e4b\u4e0b\uff0c\u7531\u4e8e\u80bf\u7624\u4e2d\u7f3a\u4e4f CD8 T \u7ec6\u80de\uff0c\u5355\u72ec\u4f7f\u7528\u6297 PD-1\/PD-L1 \u53ef\u80fd\u65e0\u6cd5\u5b8c\u5168\u6709\u6548\u5730\u6cbb\u7597 ccrcc1\u3002\u53e6\u4e00\u79cd\u80fd\u591f\u5438\u5f15\u80bf\u7624\u4e2d T \u7ec6\u80de\u7684\u7597\u6cd5\uff0c\u4f8b\u5982\u8840\u7ba1\u751f\u6210\u6291\u5236\u5242\uff08VEGFR-TKI \u6216\u6297 VEGF mAb\uff09\u6216 CTLA4 \u963b\u65ad\u5242\uff0c\u53ef\u4ee5\u4f7f\u80bf\u7624\u5bf9\u6297 PD-1\/PD-L1 \u7597\u6cd5\u654f\u611f\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u56e0\u6b64\uff0c\u6211\u4eec\u63d0\u51fa\u5206\u5b50\u548c\u514d\u75ab\u4fe1\u53f7\u7279\u5f81\u7684\u7ec4\u5408\u53ef\u80fd\u6bd4\u5355\u72ec\u7684\u4fe1\u53f7\u80fd\u591f\u66f4\u597d\u5730\u9884\u6d4b CBT \u7597\u6548\u3002Fig2.4<\/span>\u663e\u793a\u4e86\u5982\u4f55\u5728 ccRCC \u4e2d\u7ed3\u5408\u591a\u79cd\u751f\u7269\u6807\u5fd7\u7269\u6765\u5e2e\u52a9\u60a3\u8005\u505a\u51fa\u66f4\u597d\u5730\u9009\u62e9\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
<\/section>\n<\/section>\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

Fig 2.4<\/span> \u751f\u7269\u6807\u5fd7\u7269\u9a71\u52a8\u6cbb\u7597\u7684\u6574\u5408\u89c6\u56fe<\/span><\/strong>\uff1accRCC\u7684\u793a\u4f8b\u3002\u6839\u636eBeuselinck\u7b49\u4eba\u7684\u5206\u5b50\u7ec4\u5206\u7c7b\u5668\uff0c\u786e\u5b9a\u4e86\u56db\u7ec4\uff08ccrcc1\u81f34\uff09\u5bf9Sunitin<\/span>ib\u6709\u660e\u663e\u53cd\u5e94\u7684\u60a3\u8005\uff0c\u5176\u4e2dccrcc3\u7684\u53cd\u5e94\u6700\u597d\u3002ccrcc\u5206\u5b50\u578b\u5177\u6709\u4e0d\u540c\u7684\u57fa\u56e0\u8868\u8fbe\u514d\u75ab\u8c31\uff1a\u514d\u75ab\u8352\u6f20\u578b\uff08ccrcc1\uff09\uff0c\u514d\u75ab\u6d3b\u6027\u578b\uff08ccrcc3\uff09\uff0c\u514d\u75ab\u9ad8<\/span>\u578b (ccrcc4)\u548c\u6df7\u5408\u578b(ccrcc2)\u80bf\u7624\u3002\u514d\u75ab\u7ec4\u5316\u68c0\u6d4bCD8+ <\/sup>T\u7ec6\u80de\u6d78\u6da6\u8bc1\u5b9e\u4e86\u8fd9\u56db\u79cd\u8868\u578b\u3002\u57fa\u4e8e\u514d\u75ab\u8c03\u8282\u68c0\u67e5\u70b9\u53ca\u5176\u914d\u4f53\u7684\u57fa\u56e0\u8868\u8fbe\u7684T\u7ec6\u80de\u6291\u5236\u4fe1\u53f7\u7ec6\u5316\u4e86\u56db\u79cd\u514d\u75ab\u8868\u578b\uff0c\u5e76\u63d0\u4f9b\u4e86\u989d\u5916\u7684\u4fe1\u606f\u6765\u5e2e\u52a9\u60a3\u8005\u8fdb\u884c\u6cbb\u7597\u9009\u62e9\u3002ccrcc1\u80bf\u7624\u662f\u514d\u75ab\u8352\u6f20\uff0c<\/span>\u60a3\u8005\u53ef\u80fd\u53d7\u76ca\u4e8e\u57fa\u4e8eT\u7ec6\u80de\u5438\u5f15\u5242\u7684\u6cbb\u7597\uff0c\u5982\u75ab\u82d7\u6216CAR-T\u7ec6\u80de\u6216\u8fc7\u7ee7T\u7ec6\u80de\u8f6c\u79fb;ccrcc4\u80bf\u7624\u514d\u75ab\u529f\u80fd\u9ad8\uff0cT\u7ec6\u80de\u5bc6\u5ea6\u9ad8\uff0c\u514d\u75ab\u8c03\u8282\u68c0\u67e5\u70b9\u9ad8\u8868\u8fbe; \u5355\u7eaf\u6297pd -(L)1\u53ef\u4f7fccrcc4\u60a3\u8005\u83b7\u76ca\u3002ccrcc3\u80bf\u7624\u5177\u6709\u514d\u75ab\u6d3b\u6027\uff0cT\u7ec6\u80de\u5927\u91cf\u6d78\u6da6\uff0c\u4f46\u514d\u75ab\u8c03\u8282\u68c0\u67e5\u70b9\u4f4e\u8868\u8fbe; \u4ec5VEGFR-TKI\u5728\u8fd9\u4e00ccrcc3\u7ec4\u60a3\u8005\u4e2d\u663e\u793a\u51fa\u826f\u597d\u7684\u7ed3\u679c\u3002\u5728T\u7ec6\u80de\u6d78\u6da6\u548c\u514d\u75ab\u8c03\u8282\u68c0\u67e5\u70b9\u8868\u8fbe\u65b9\u9762\uff0cccrcc2\u80bf\u7624\u662f\u6df7\u5408\u7684; ccrcc2\u60a3\u8005\u53ef\u6839\u636eT\u7ec6\u80de\u6d78\u6da6\u548c\u514d\u75ab\u8c03\u8282\u68c0\u67e5\u70b9\u7684\u8868\u8fbe\u60c5\u51b5\u8fdb\u884c\u6cbb\u7597<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u4e3a\u4e86\u8bc1\u5b9e\u8fd9\u4e9b\u5047\u8bbe\uff0c\u6211\u4eec\u4e8e2017\u5e743\u6708\u542f\u52a8\u4e86\u8fc4\u4eca\u4e3a\u6b62\u7b2c\u4e00\u4e2a\u751f\u7269\u6807\u5fd7\u7269\u9a71\u52a8\u7684ccRCC\u8bd5\u9a8c\uff0c\u79f0\u4e3aBIONIKK\uff08\u751f\u7269\u6807\u5fd7\u7269\u9a71\u52a8\u7684\u8bd5\u9a8c\uff0c\u5728na\u00efve\u8f6c\u79fb\u6027\u80be\u764c\u4e2d\u4f7f\u7528Nivolumab\u548cIpilimumab\u6216Vegfr  TKI\uff0cNCT02960906\u8fdb\u884c\u6cbb\u7597\uff09\u3002\u8be5\u8bd5\u9a8c\u4e2dmRCC\u60a3\u8005\u968f\u673a\u63a5\u53d7nivolumab(\u6297PD -1)\u3001ipilimumab(\u6297CTLA-4)\u3001\u8054\u5408\u6216TKI(\u6839\u636e\u5176\u5206\u5b50\u4e9a\u7ec4)\u7684\u4e00\u7ebf\u5168\u8eab\u6cbb\u7597\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u6839\u636e\u6cbb\u7597\u548c\u5206\u5b50\u7ec4\u7684\u5ba2\u89c2\u53cd\u5e94\u7387\u3002\u4f7f\u7528IHC\u548c\u57fa\u56e0\u8868\u8fbe\u5206\u6790\uff08MCP-COUNTION\uff09\u8bc4\u4f30\u514d\u75ab\u6d78\u6da6\u53ca\u5176\u4e0e\u7ed3\u679c\u548c\u5206\u5b50\u5206\u578b\u7684\u76f8\u5173\u6027\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

\u7ed3\u8bba<\/strong><\/p>\n<\/section>\n

\n
\n
\n

\u80bf\u7624\u7ec6\u80de\u4e0e\u5bbf\u4e3b\u4e4b\u95f4\u7684\u590d\u6742\u76f8\u4e92\u4f5c\u7528\u786e\u5b9a\u4e86\u514d\u75ab\u73af\u5883\u7684\u6982\u5ff5\uff0c\u5176\u4e2d\u5305\u62ec TME \u4e2d\u514d\u75ab\u7ec6\u80de\u7684\u7ec4\u7ec7\u3001\u4f4d\u7f6e\u3001\u5bc6\u5ea6\u548c\u529f\u80fd\u3002\u8fd9\u79cd\u514d\u75ab\u73af\u5883\u6709\u52a9\u4e8e\u4e86\u89e3\u652f\u6301\u5404\u79cd\u514d\u75ab\u53cd\u5e94\u7ec6\u80de\u7684\u4e34\u5e8a\u5f71\u54cd\u7684\u75c5\u7406\u751f\u7406\u673a\u5236\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u591a\u79cd\u80bf\u7624\u7c7b\u578b\u4e2d\u9776\u5411PD-1\/PD-L1 \u7684CBT\u7684\u6279\u51c6\u7387\u4e0d\u65ad\u4e0a\u5347\uff0c\u4f7f\u5f97\u4e16\u754c\u5404\u5730\u7684\u7814\u7a76\u56e2\u961f\u6df1\u5165\u63a2\u7d22\u514d\u75ab\u73af\u5883\uff0c\u4ece\u800c\u66f4\u597d\u5730\u4f18\u5316\u8fd9\u4e9b\u5236\u5242\u7684\u529f\u6548\u3002\u6b64\u5916\uff0c\u76ee\u524d\u5728\u4e34\u5e8a\u8bd5\u9a8c\u8bc4\u4f30\u4e2d\u7684\u4f53\u5185\u6ce8\u5c04\u836f\u7269\u6570\u91cf\u5e9e\u5927\uff0c\u4f7f\u5f97\u76f8\u5173\u516c\u53f8\u4e4b\u95f4\u7ade\u4e89\u975e\u5e38\u6fc0\u70c8\uff0c\u8fd9\u53cd\u8fc7\u6765\u8feb\u4f7f\u4ed6\u4eec\u7406\u89e3\u7b5b\u9009\u60a3\u8005\u7684\u91cd\u8981\u6027\uff0c\u5e76\u4f5c\u51fa\u8d22\u653f\u52aa\u529b\u6765\u652f\u6301\u8f6c\u5316\u7814\u7a76\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u76ee\u524d\u5df2\u7ecf\u505a\u4e86\u5f88\u591a\u52aa\u529b\u6765\u5bfb\u627e\u4e00\u79cd\u65b9\u6cd5\u6765\u7b5b\u9009\u53ef\u4ece CBT \u4e2d\u6301\u4e45\u83b7\u76ca\u7684\u60a3\u8005\u3002\u80bf\u7624\u6d78\u6da6\u514d\u75ab\u7ec6\u80de\u7684\u8868\u5f81\u53ef\u80fd\u662f\u6700\u6709\u5e0c\u671b\u7684\u6709\u6548\u751f\u7269\u6807\u5fd7\u7269\u4e4b\u4e00\u3002\u6280\u672f\u65b9\u9762\u7684\u6311\u6218\u662f\u8fd9\u4e9b\u6709\u524d\u9014\u7684\u751f\u7269\u6807\u5fd7\u7269\u4e0d\u53ef\u91cd\u590d\u6216\u96be\u4ee5\u8bc4\u4f30\u7684\u539f\u56e0\uff0c\u8fd9\u4e9b\u6311\u6218\u4e4b\u4e00\u662f IHC \u6216 IF \u6280\u672f\u6240\u56fa\u6709\u7684\u3002\u5373\u4f7f\u5728\u8be5\u9886\u57df\u53d6\u5f97\u4e86\u91cd\u5927\u8fdb\u5c55\uff0c\u6211\u4eec\u4e5f\u5fc5\u987b\u5904\u7406\u80bf\u7624\u5185\u5f02\u8d28\u6027\u548c\u7f3a\u4e4f\u7279\u5b9a\u6807\u8bb0\u7269\u7684\u95ee\u9898\uff0c\u5e76\u89e3\u51b3\u52a8\u6001\u8fc7\u7a0b\u7684\u8bc4\u4f30\u95ee\u9898\u3002\u524d\u4e24\u70b9\u53ef\u4ee5\u901a\u8fc7\u8f6c\u5f55\u7ec4\u5206\u6790\u65b9\u9762\u7684\u8fdb\u5c55\u90e8\u5206\u89e3\u51b3\uff0c\u7279\u522b\u662f\u5728\u6700\u8fd1\u5f00\u53d1\u7684\u514d\u75ab\u8868\u5f81\u65b9\u6cd5\u4f8b\u5982\u5728 MCP-counter \u4e2d\u3002MCP-counter \u5728\u5b9a\u4e49\u514d\u75ab\u7ec6\u80de\u7684\u6bd4\u4f8b\u65b9\u9762\u5177\u6709\u5f88\u9ad8\u7684\u51c6\u786e\u6027\uff0c\u53ef\u91cd\u590d\u6027\u597d\uff0c\u5bf9\u80bf\u7624\u5f02\u8d28\u6027\u7684\u4f9d\u8d56\u6027\u8f83\u5c0f\uff0c\u5e76\u6700\u7ec8\u5141\u8bb8\u5728\u80bf\u7624\u7c7b\u578b\u4e4b\u95f4\u8fdb\u884c\u6bd4\u8f83\u3002\u4f7f\u7528 NGS\u6d4b\u5e8f\u3001RNA \u6d4b\u5e8f\uff0c\u591a\u91cd IF \u5bf9\u514d\u75ab TME \u7684\u8868\u5f81\u4ee5\u53ca\u6076\u6027\u7ec6\u80de\u7684\u6df1\u5ea6\u8868\u5f81\uff0c\u4f7f\u5f97\u5c06\u6700\u5408\u9002\u7684\u7cbe\u51c6\u836f\u7269\u7528\u6765\u6cbb\u7597\u60a3\u8005\u5e76\u5bc6\u5207\u76d1\u6d4b CBT \u671f\u95f4\u7684\u52a8\u6001\u53d8\u5316\u6210\u4e3a\u53ef\u80fd\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u672c\u6587\u7531Oncolab\u5fae\u4fe1\u516c\u4f17\u53f7\u7ffb\u8bd1\u6574\u7406\u81eaOncoimmunology: A Practical Guide for Cancer Immunotherapy\uff0c\u4ec5\u7528\u4e8e\u5b66\u4e60\u4ea4\u6d41\u4f7f\u7528\uff0c\u5982\u9700\u8d2d\u4e70\u539f\u7248\u4e66\u7c4d\u53ef\u70b9\u51fb\u9605\u8bfb\u539f\u6587\u8d2d\u4e70\u3002<\/span>
<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u2014 THE  END \u2014<\/span><\/p>\n


<\/p>\n

\u6765\u6e90 | Oncoimmunology: A Practical Guide <\/span><\/p>\n

for Cancer Immunotherapy<\/span><\/p>\n

\u4f5c\u8005 | Laurence Zitvogel \u2022 Guido Kroemer<\/span><\/p>\n

\u7ffb\u8bd1 |   \u9648\u4f73\u8587 \u949f\u96ea\u83b9 \u7f57\u6e05\u7075<\/span><\/section>\n
\u7f16\u8f91\u6392\u7248 | \u848b\u4fca\u535a<\/span><\/span><\/section>\n
\u521d\u5ba1 | \u5b8b\u4e50 \u9648\u79cb\u8c37<\/span><\/section>\n
\u7ec8\u5ba1 | \u8096\u5efa\u52c7 \u738b\u5764<\/span><\/section>\n
\uff08\u8f6c\u8f7d\u8bf7\u4fdd\u7559\u6b64\u90e8\u5206\u5185\u5bb9\uff09<\/span><\/strong><\/section>\n

<\/section>\n

\u2589  \u5f80\u671f\u6587\u7ae0\u76ee\u5f55<\/strong><\/strong><\/p>\n

\u57fa\u7840\u514d\u75ab\u5b66\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c22\u7ae0\uff1a\u514d\u75ab\u7cfb\u7edf\u7684\u6740\u4f24\u529f\u80fd<\/span><\/a><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c21\u7ae0\uff1a\u541e\u566c\u7ec6\u80de<\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c20\u7ae0\uff1a\u56fa\u6709\u514d\u75ab\u7684\u9632\u5fa1\u4f5c\u7528<\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c19\u7ae0\uff1a\u514d\u75ab\u7cfb\u7edf\u751f\u7406\u529f\u80fd\u7b80\u8ff0<\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c18\u7ae0\uff1a\u514d\u75ab\u7cfb\u7edf\u7684\u8c03\u8282<\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c17\u7ae0\uff1a\u514d\u75ab\u8bb0\u5fc6\u4e0e\u6dcb\u5df4\u7ec6\u80de\u7a33\u6001<\/span><\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c16\u7ae0\uff1aT\u7ec6\u80de\u4e0e\u5176\u4ed6\u514d\u75ab\u7ec6\u80de\u95f4\u7684\u76f8\u4e92\u4f5c\u7528<\/a><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c15\u7ae0\uff1aT\u7ec6\u80de\u7684\u53d1\u80b2<\/a><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c14\u7ae0\uff1aB\u7ec6\u80de\u7684\u53d1\u80b2<\/a><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c13\u7ae0\uff1a\u514d\u75ab\u7cfb\u7edf\u7684\u5668\u5b98\u548c\u7ec4\u7ec7<\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c12\u7ae0\uff1a\u9020\u8840\u529f\u80fd-\u8840\u7ec6\u80de\u751f\u6210<\/a>
<\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c11\u7ae0\uff1a\u6dcb\u5df4\u7ec6\u80de\u6d3b\u5316<\/a><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c10\u7ae0\uff1a\u6297\u539f\u7684\u5904\u7406\u548c\u5448\u9012<\/a><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c9\u7ae0\uff1a\u6297\u539f\u8bc6\u522b\u7814\u7a76\u8fdb\u5c55<\/a><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c8\u7ae0\uff1a\u4e3b\u8981\u7ec4\u7ec7\u76f8\u5bb9\u6027\u590d\u5408\u7269MHC<\/a><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c7\u7ae0\uff1aT\u7ec6\u80de\u53d7\u4f53(TCR)\u6982\u8ff0<\/a>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c6\u7ae0\uff1a\u6297\u4f53\u591a\u6837\u6027<\/a><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c5\u7ae0\uff1a\u6297\u4f53-\u6297\u539f\u76f8\u4e92\u4f5c\u7528<\/a><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c4\u7ae0\uff1a\u6297\u539f\u548c\u6297\u4f53\u7ed3\u6784<\/a><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c3\u7ae0\uff1a\u6297\u539f\u8bc6\u522b<\/a><\/span><\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c2\u7ae0\uff1a\u514d\u75ab\u7cfb\u7edf\u7684\u57fa\u672c\u6982\u5ff5\u548c\u7ec4\u6210<\/a><\/span>
<\/p>\n

\u514d\u75ab\u5b66\u62fe\u9057-\u7b2c1\u7ae0\uff1a\u514d\u75ab\u7cfb\u7edf\u7b80\u4ecb<\/a><\/span><\/p>\n

\u80bf\u7624\u514d\u75ab\u5b66\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c2\u7ae0\uff1a\u4eba\u7c7b\u80bf\u7624\u5fae\u73af\u5883\uff08\u4e0a\uff09<\/a>
<\/span><\/p>\n

\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c1\u7ae0\uff1a\u80bf\u7624\u514d\u75ab\u7b80\u53f2<\/span><\/a>
<\/p>\n

\u80bf\u7624\u514d\u75ab\u5b66\u7cfb\u5217\u66f4\u65b0\u9884\u544a<\/span><\/a><\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c7\u5929)-210608<\/a>
<\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c6\u5929)-210607<\/a>
<\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c5\u5929)-210605<\/a>
<\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c4\u5929)-210604<\/a><\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c3\u5929)-210603<\/span><\/a>
<\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c1\u5929)-20210531<\/a><\/span><\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0(\u7b2c2\u5929)-20210601<\/a><\/p>\n

TCGA\u514d\u75ab\u6d78\u6da6\u8bc4\u4ef7\u6570\u636e\u5e93<\/a>
<\/p>\n

ggplot2|\u8be6\u89e3\u516b\u5927\u57fa\u672c\u7ed8\u56fe\u8981\u7d20<\/a>
<\/p>\n

Python\u96c6\u6210\u5f00\u53d1\u73af\u5883PyCharm\u7684\u5b89\u88c5\u4e0e\u6fc0\u6d3b<\/a>
<\/p>\n

Python\u53d1\u884c\u7248Anaconda\u7684\u5b89\u88c5\u4e0e\u4f7f\u7528<\/a><\/p>\n

\u57fa\u7840\u5b9e\u9a8c\u6280\u672f\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u6d41\u5f0f\u68c0\u6d4b\u7ec6\u80de\u603bROS-OncoLab\u5b9e\u9a8c\u5ba4<\/a><\/span>
<\/p>\n

Annexin V\/PI\u67d3\u8272\u68c0\u6d4b\u7ec6\u80de\u51cb\u4ea1-OncoLab\u5b9e\u9a8c\u5ba4<\/a>
<\/p>\n

\u514d\u75ab\u8367\u5149\u5b9e\u9a8c-OncoLab\u5b9e\u9a8c\u5ba4<\/a>
<\/p>\n

WB\u64cd\u4f5c\u89c6\u9891-OncoLab\u5b9e\u9a8c\u5ba4<\/a><\/span><\/p>\n

QPCR\u5b9e\u9a8c\u64cd\u4f5c\u89c6\u9891-OncoLab\u5b9e\u9a8c\u5ba4<\/a>
<\/p>\n

\u4eea\u5668\u64cd\u4f5c\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u5c0f\u52a8\u7269\u6d3b\u4f53\u5149\u5b66\u6210\u50cf\u7cfb\u7edf\u64cd\u4f5c\u89c6\u9891-\u4e2d\u897f\u533b\u7ed3\u5408\u57fa\u7840\u7814\u7a76\u4e2d\u5fc3<\/a>
<\/p>\n

\u8521\u53f8LSM800\u6fc0\u5149\u5171\u805a\u7126\u663e\u5fae\u955c\u64cd\u4f5c\u89c6\u9891-\u4e2d\u897f\u533b\u7ed3\u5408\u57fa\u7840\u7814\u7a76\u4e2d\u5fc3<\/a>
<\/p>\n

IN Cell Analyzer2200\u9ad8\u5185\u6db5\u7ec6\u80de\u6210\u50cf\u5206\u6790\u7cfb\u7edf\u64cd\u4f5c\u6559\u7a0b-\u4e2d\u897f\u533b\u7ed3\u5408\u57fa\u7840\u7814\u7a76\u4e2d\u5fc3<\/a>
<\/p>\n

BD LSR Fortessa\u6d41\u5f0f-\u4e2d\u897f\u533b\u7ed3\u5408\u57fa\u7840\u7814\u7a76\u4e2d\u5fc3<\/a><\/span><\/p>\n

\u6587\u732e\u5206\u4eab\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u80bf\u7624\u4ee3\u8c22\u91cd\u7f16\u7a0b\u4e0e\u514d\u75ab\u5e94\u7b54<\/a>
<\/p>\n

\u5e74\u5ea6\u5de8\u732e\uff1a\u795e\u520aCA\u53d1\u5e03\u6700\u65b0\u764c\u75c7\u6570\u636e\uff1a\u5168\u74031000\u4e07\u4eba\u6b7b\u4e8e\u764c\u75c7\uff0c\u4e2d\u56fd\u5360\u6bd4\u8d853\u6210<\/a>
<\/p>\n

HLA-I\u5206\u5b50\u52a0\u5de5\u548c\u9012\u5448\u6297\u539f\u529f\u80fd\u53d7\u635f\u662f\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u8010\u836f\u7684\u91cd\u8981\u539f\u56e0<\/a>
<\/p>\n

PD-1\/PD-L1\u963b\u65ad\u5242\u6cbb\u7597\u80bf\u7624\u7684\u7814\u7a76\u8fdb\u5c55\u4e0e\u9762\u4e34\u7684\u6311\u6218<\/a><\/span><\/p>\n

Immunity\uff1a\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u7684\u5341\u5927\u6311\u6218<\/span><\/a><\/p>\n

\u4f5c\u56fe\u6295\u7a3f\u9009\u520a\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

GraphPad+AI\u5236\u4f5c\u53ef\u53d1\u8868\u7ea7\u522b\u7684\u67f1\u72b6\u56fe-OncoLab\u5b9e\u9a8c\u5ba4<\/a>
<\/p>\n

\u5982\u4f55\u4f7f\u7528ImageJ\u8fdb\u884c\u7ec6\u80de\u8367\u5149\u5b9a\u91cf<\/a>
<\/p>\n

\u5982\u4f55\u4f7f\u7528Scrivener\u8fdb\u884c\u79d1\u6280\u8bba\u6587\u5199\u4f5c<\/a>
<\/p>\n

Mendeley-\u6700\u597d\u7528\u7684\u6587\u732e\u9605\u8bfb\u7ba1\u7406\u8f6f\u4ef6\uff0c\u6ca1\u6709\u4e4b\u4e00<\/a>
<\/p>\n

\u5982\u4f55\u9009\u62e9\u4e00\u4e2a\u5408\u9002\u7684\u6742\u5fd7\u8fdb\u884c\u6295\u7a3f\uff1f<\/a>
<\/p>\n

PubMed\u4e2d\u5982\u4f55\u6309\u5f71\u54cd\u56e0\u5b50\u7b5b\u9009\u68c0\u7d22\u7ed3\u679c\u5e76\u663e\u793a\u5f71\u54cd\u56e0\u5b50\u53ca\u5206\u533a\uff1f<\/a>
<\/p>\n

\u5982\u4f55\u4f7f\u7528EndNote\u8f6f\u4ef6\u63d2\u5165\u53c2\u8003\u6587\u732e\uff08\u96446813\u79cd\u6742\u5fd7\u53c2\u8003\u6587\u732e\u683c\u5f0f\u6587\u4ef6\uff09<\/a><\/span><\/p>\n

\u5065\u5eb7\u517b\u751f\u7cfb\u5217<\/strong><\/strong><\/span><\/p>\n

\u516b\u6bb5\u9526\uff08\u89c6\u9891\u7248+\u56fe\u7247\u7248\uff0c\u63a8\u8350\u6536\u85cf\uff09<\/span><\/a>
<\/p>\n


<\/p>\n


<\/p>\n

\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n

<\/p>\n

\u5173\u6ce8\u672c\u53f7~<\/span><\/p>\n


<\/p>\n

<\/p>\n

\u52a0\u5165\u8bfb\u8005\u4ea4\u6d41\u7fa4~<\/span><\/p>\n


<\/p>\n


<\/p>\n


<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u70b9\u4eae\u201c\u5728\u770b\u201d<\/span><\/section>\n
\u8ba9\u66f4\u591a\u4eba\u770b\u5230\uff01<\/span><\/section>\n
\n

\u672c\u7bc7\u6587\u7ae0\u6765\u6e90\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7: OncoLab <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u5728\u4e0a\u671f\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c2\u7ae0\uff1a\u4eba\u7c7b\u80bf\u7624\u5fae\u73af\u5883\uff08\u4e0a\uff09\u4e2d\u5df2\u7ecf\u5bf9\u80bf\u7624\u514d\u75ab\u5b66\u53ca\u764c\u75c7\u7684\u53d1\u5c55\u8fdb\u884c\u4e86\u7b80\u8981\u4ecb\u7ecd\uff0c\u5e76\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u7684…<\/p>\n","protected":false},"author":1,"featured_media":2154,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":[],"categories":[65],"tags":[],"_links":{"self":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/2159"}],"collection":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/comments?post=2159"}],"version-history":[{"count":1,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/2159\/revisions"}],"predecessor-version":[{"id":2482,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/2159\/revisions\/2482"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/media\/2154"}],"wp:attachment":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/media?parent=2159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/categories?post=2159"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/tags?post=2159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}